Why Repurposed Drugs Like Metformin Aren’t Fully Studied for Cancer (and Why It Matters)
We like to think innovation is everywhere. New apps. New drugs. New tools.
But what if some of the most important breakthroughs…simply never happen?
Not because they’re impossible. But because they’re unprofitable!
This is the invisible problem inside our healthcare innovation system, one that’s costing us billions in potential discoveries, and worse, countless lives.
Key Takeouts
- The problem isn’t science, it’s incentives. Our system rewards patentability, not impact.
- New uses for existing drugs are often ignored. Once a drug goes generic, no company will fund research without profit protections.
- Metformin is a prime example. This diabetes drug shows early signs it could help in cancer, however, no large trials were funded.
- The cost is staggering. Between 200 and 800 drug uses valued at $2–10 trillion have been lost.
- We need new models. Innovation must be driven by public good, not just private gain.
Why Don’t Companies Study Repurposed Drugs for Cancer?
A new study from researchers at the University of Chicago, Stanford, Dartmouth, and others confirms what many in healthcare have long suspected:
Our system doesn’t reward the most impactful innovations. It rewards the most protectable ones.
That’s why new uses for existing drugs and some of the most promising, low-cost opportunities in medicine often go undeveloped.
Why Generics Stop Research
When a drug is first approved, the company that developed it has exclusive rights for a period of time.
Those exclusivities allow them to sell the drug without competition, which helps cover the billions spent on research and development.
But once the patent expires, generic versions enter the market.
These generics are chemically identical, but far cheaper. That’s good news at the pharmacy counter.
The problem?
It removes the financial incentive to study new uses.
Even if a clinical trial showed that a generic drug could help with cancer or Alzheimer’s (and any doctor could prescribe the low-cost generic) the company funding the research would have no way to recover its investment.
So while the science may be promising, the business case collapses. And the research simply doesn’t get done.
Metformin and Cancer: A Case of Missed Innovation
Take metformin, a common generic for diabetes.
Doctors noticed signs it might also help fight certain cancers. Researchers were eager to test it. But no company stepped up to fund the large-scale clinical trials.
Why?
Because even if those trials proved that metformin is indeed effective for cancer, the company paying for the research would get locked out of revenue.
The result: the science stalled.
The potential was real. The incentive was gone.
And the innovation? It never happened.
Patients like Tim, who after being diagnosed with stage 4 cancer, combined repurposed drugs with lifestyle changes, show why this kind of research matters. Read Tim’s story here.
The Cost of Ignoring Repurposed Drugs For Cancer
The paper estimates that between 200 and 800 potential new drug uses have been lost to this system failure.
The social cost? Somewhere between $2 and $10 trillion.
Not in hypothetical dollars.
In real health outcomes. In treatments never discovered. In patients who never benefited.
Fixing the Innovation Gap in Healthcare
This is more than an academic finding. It’s a wake-up call.
If we want better healthcare outcomes, if we want to unlock innovation that improves lives…We need to stop asking “Can it be patented?” And start asking “Does it deserve to exist?”
Because the absence of enforceable intellectual property rights shouldn’t be the death sentence for discoveries that could save lives.
The Future of Repurposed Cancer Drugs
Every year, patients ask us about drugs like metformin, fenbendazole, or ivermectin. They’ve read stories, seen videos, or heard from others who tried them.
What’s missing is clear guidance. The science may still be evolving, but patients shouldn’t be left in the dark.
That’s where Heal Navigator steps in helping you understand what’s known, what’s still uncertain, and how to ask the right questions on your care journey.
👉 This blog was inspired by the July 2025 study, “Missing Markets for Innovation: Evidence from New Uses for Existing Drugs”
